Mesenchymal stem cell therapy for immune-modulation: the donor, the recipient, and the drugs in-between

Authors

  • Krisztian Nemeth

    Corresponding author
    1. Department of Dermatology, Dermatooncology, and Venerology, Semmelweis University, Budapest, Hungary
    • Correspondence: Krisztian Nemeth, MD, PhD, Semmelweis University, Department of Dermatology, Dermatooncology, and Venerology, Budapest, Hungary, Tel.: +36-1-459-1500, Fax: +36-1-267-6971, e-mail: nemeth.krisztian@med.semmelweis-univ.hu

    Search for more papers by this author

Abstract

Adoptive transfer of cultured bone marrow stromal cells (mesenchymal stem cells also known as MSCs) is a promising new way to aid tissue regeneration and treat a wide variety of diseases where regulation of inflammatory responses is derailed. Although significant advances have been made in the field, pinpointing important mechanistic details about how MSCs function in vitro and in vivo, there are still many unanswered questions that need to be addressed before welcoming MSCs in the therapeutic arsenal of immune mediated diseases. In this viewpoint, we highlight and discuss a few factors that we believe are critical in terms of therapeutic success employing cultured MSCs. Selecting the right donor population, choosing the best culture conditions and picking the patient population that is most likely to give a favourable therapeutic response is just as important as considering interactions between MSCs and the combination of drugs in the recipient's body. Given the complexity of MSC–host interactions, it is also imperative to develop screening tools that account for as many variables as possible and predict precisely the in vivo response rates before MSCs enter the body. To achieve this, a multidisciplinary approach is required with comprehensive knowledge of basic MSC biology, immunology, pharmacology and good clinical practice.

Ancillary